Fusion Antibodies Overview

  • Founded
  • 2001
Founded
  • Status
  • Public
  • Employees
  • 39
Employees
  • Stock Symbol
  • FAB
Stock Symbol
  • Share Price
  • $1.73
  • (As of Wednesday Closing)

Fusion Antibodies General Information

Description

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
LON
Primary Office
  • 1 Springbank Road
  • Springbank Industrial Estate
  • Belfast BT17 0QL
  • Northern Ireland, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Fusion Antibodies Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.73 $1.73 $0.97 - $3.31 $44.7M 25.9M 16.3K -$0.15

Fusion Antibodies Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019
EV 51,493 51,493 24,708 4,646
Revenue 5,435 5,435 4,948 2,864
EBITDA (698) (698) (555) (1,413)
Net Income (3,783) (3,783) (885) (1,659)
Total Assets 8,013 8,013 7,471 8,143
Total Debt 316 316 470 183
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Fusion Antibodies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Fusion Antibodies‘s full profile, request access.

Request a free trial

Fusion Antibodies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Fusion Antibodies‘s full profile, request access.

Request a free trial

Fusion Antibodies Executive Team (5)

Name Title Board Seat Contact Info
Richard Jones Ph.D Chief Executive Officer
James Fair Chief Financial Officer
Richard Buick Ph.D Board Member & Executive
You’re viewing 3 of 5 executive team members. Get the full list »

Fusion Antibodies Board Members (10)

Name Representing Role Since
Alan Mawson Ph.D Clarendon Fund Managers Board Member 000 0000
Colin Walsh Crescent Capital Board Member 000 0000
Richard Buick Ph.D Fusion Antibodies Board Member & Executive 000 0000
Simon Douglas Ph.D Self Chairman & Board Member 000 0000
Sonya Ferguson Fusion Antibodies Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Fusion Antibodies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Fusion Antibodies Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Fusion Antibodies‘s full profile, request access.

Request a free trial